Status:
NOT_YET_RECRUITING
Sphingolipids in Asthma Pathogenesis
Lead Sponsor:
Peking University Third Hospital
Conditions:
Asthma
Eligibility:
All Genders
18-80 years
Brief Summary
The study aims to investigate the relationship between the small molecule metabolite sphingolipids and asthma clinical features and explore its involvement in asthma pathogenesis.
Eligibility Criteria
Inclusion
- 1\. clinical diagnosis of asthma
Exclusion
- 1\. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor 2. Combined with acute and chronic respiratory failure 3. Combined with severe cardiovascular disease 4. Pregnant woman.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06539221
Start Date
September 1 2024
End Date
September 1 2026
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking university third hospital
Beijing, Beijing Municipality, China, 100191